[Omalizumab in severe asthma--case report].
We describe the case of 31-year-old woman whose severe asthma was not properly controlled with best available therapy according to GINA (2002). Following administration of anti-IgE monoclonal antibody she experienced significant improvement in her asthma control
Gawlewicz-Mroczka
Agnieszka
A
Klinika Pulmonologii II Katedry Chorób Wewnetrznych CM UJ w Krakowie.
Nizankowska-Mogilnicka
Ewa
E
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069444:Omalizumab; D011788:Quality of Life; D012221:Rhinitis, Allergic, Perennial / Q000150:complications; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab